Moderna's vaccine may be best against Delta variant
The mRNA vaccine from Pfizer (PFE.N) and BioNTech (22UAy.DE) may be less effective than Moderna's against the Delta variant of the coronavirus, according to two reports posted on medRxiv on Sunday ahead of peer review, Reuters reports.
76% efficiency in July
In a study of more than 50,000 patients in the Mayo Clinic Health System, researchers found the effectiveness of Moderna's vaccine against infection had dropped to 76% in July - when the Delta variant was predominant - from 86% in early 2021.
Over the same period, the effectiveness of the Pfizer/BioNTech vaccine had fallen to 42% from 76%, researchers said.
A Moderna booster shot may be necessary soon
While both vaccines remain effective at preventing COVID hospitalization, a Moderna booster shot may be necessary soon for anyone who got the Pfizer or Moderna vaccines earlier this year, said Dr. Venky Soundararajan of Massachusetts data analytics company nference, who led the Mayo study.
In a separate study, elderly nursing home residents in Ontario produced stronger immune responses - especially to worrisome variants - after the Moderna vaccine than after the Pfizer/BioNTech vaccine.
The elderly may need higher vaccine doses, boosters, and other preventative measures, said Anne-Claude Gingras of the Lunenfeld-Tanenbaum Research Institute in Toronto, who led the Canadian study.
When asked to comment on both research reports, a Pfizer spokesperson said,
We continue to believe... a third dose booster may be needed within 6 to 12 months after full vaccination to maintain the highest levels of protection."